Hints and tips:
Related Special Reports
...“All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit,” he said....
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share price towards...
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...Shares in the two companies have soared; after years of trading at a mid-to-late teens forward price/earnings ratio, Novo now commands 32 times and Lilly almost 42 times, on FactSet figures....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...Amazon Pharmacy stands to generate “a lot of revenue” from drugs such as Eli Lilly’s Zepbound injection and Novo Nordisk’s Wegovy, which are both available to patients directly through the Amazon website...
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Novo Nordisk is lowering prices of its weight loss drug Wegovy as it boosts sales volumes and responds to higher competition from US rival Eli Lilly, leading to lower than expected quarterly revenue from...
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...It trades on a price/earnings multiple of 50 times, the kind of hefty multiple normally associated with obesity stocks. Novo Nordisk is on a 37 times multiple and Eli Lilly on 59 times....
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
International Edition